Vela Diagnostics have received FDA De Novo authorization for itsSentosaSQ HIV-1 Genotyping Assay The NGS platform detects drug-resistance mutations in the virus39Pol gene and provides results in 2 days
from rapidmicrobiology https://ift.tt/34lQv4l
No comments:
Post a Comment